Lantheus Medical Imaging of North Billerica, MA, said that new data from a phase IV safety study of its Definity echocardiography contrast agent have added further validation to the agent's safety profile.
In research presented at the annual American Society of Echocardiography (ASE) scientific sessions in San Diego this week, Definity use did not result in any clinically or statistically significant changes in systemic or pulmonary artery hemodynamic measurements in patients with either normal or increased baseline pulmonary artery pressure, according to the firm.
Kevin Wei, MD, of Oregon Health and Science University presented the study.
Related Reading
Lantheus' F-18 PET agent shows good dosing ratio, June 11, 2010
Lantheus touts results for PET agent at SNM, June 8, 2010
Lantheus reports F-18 cardiac PET findings, June 7, 2010
Lantheus inks Ablavar contract with Amerinet, June 3, 2010
Lantheus receives Mo-99 from Europe, May 21, 2010
Copyright © 2010 AuntMinnie.com
